Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11122982 | 0.89 | TSHR (0.57) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL1237286 | 0.89 | TSHR (0.57) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL28101148 | 0.86 | TSHR (0.55) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL28669926 | 0.84 | TSHR (0.52) | TSHRALDH1A1LMNATDP1TP53 | |
| SCHEMBL1630328 | 0.81 | ALDH1A1 (0.42) | TSHRALDH1A1LMNACYP3A4ALOX15 | |
| SCHEMBL28822581 | 0.81 | TSHR (0.48) | TSHRALDH1A1TDP1TP53PPARD | |
| Trimethylammonium SCHEMBL28541031 | 0.81 | TSHR (0.48) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL29250785 | 0.80 | TSHR (0.43) | TSHRALDH1A1TDP1TP53PPARD | |
| SCHEMBL28743332 | 0.79 | TSHR (0.46) | TSHRALDH1A1LMNAHSD17B10TDP1 | |
| SCHEMBL388425 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-8239365-A | — | — | None | — | — | JP | disclosed |
| CN-119613643-A | Functionalized covalent organic framework material and preparation method and application thereof | 广东工业大学 | 2025-03-14 | — | — | CN | disclosed |
| CN-118867200-A | Nickel-rich ternary positive electrode material with double modified structures, and preparation method and application thereof | 广东工业大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-118867199-A | Nickel-rich ternary positive electrode material with coating modified structure, and preparation method and application thereof | 广东工业大学 | 2024-10-29 | — | — | CN | disclosed |
| CN-117871630-A | In-situ X-ray diffraction electrolytic cell and detection process thereof | 闽南师范大学 | 2024-04-12 | — | — | CN | disclosed |
| EP-3321261-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3321261-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | Curis, Inc. (US) | 2018-05-16 | — | — | EP | disclosed |
| EP-2661425-B1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS INC (US) | 2017-12-07 | — | — | US | disclosed |
| EP-2661425-A2 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | Curis, Inc. (US) | 2013-11-13 | — | — | EP | disclosed |
| WO-2012094328-A2 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | CURIS, INC. (US) | 2012-07-12 | — | — | WO | disclosed |
| JP-H08239365-A | 3-PHENYLISOQUINOL-1(2H)-ONE DERIVATIVE AND ITS PRODUCTION AND ITS THERAPEUTIC APPLICATION | SYNTHELABO SA | 1996-09-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349573-A1 | HEDGEHOG ANTAGONISTS HAVING ZINC BINDING MOIETIES | GLI1, SHH, HDAC1 | TSHR 1760/4885ALDH1A1 1006/4885LMNA 4754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.